- Trial Phase
- Phase 2b completed (PARADIGM); FDA clearance granted for pivotal Phase 3 (PARAGON); Health Canada NDS submission targete
- Time to Market
- Best case ~late 2027 for a Canadian approval if the December 2026 NDS is accepted and reviewed on the standard ~300-day timeline; US Phase 3 (PARAGON) is undated and likely multiple years from any approval; unknown given financing risk
- Why 4/10
- The next hard, dated drug catalyst is the targeted Health Canada New Drug Submission filing for PrimeC in ALS in December 2026 (a submission milestone, not a decision), with Health Canada's standard review of ~300 days pushing any approval binary into late 2027 and the Phase 3 PARAGON readout undated — so no qualifying approval/readout binary sits inside the next ~12 months, capping the score at 5 despite PrimeC being essentially the company's only asset.
Watch whether NeuroSense files its Health Canada NDS in December 2026 as targeted, and more urgently whether it can fund itself — the prior 20-F disclosed only ~$0.2M cash with going-concern doubt, and Nasdaq delisting notices (minimum $1.00 bid and $35M market value) carry a September 29, 2026 compliance deadline, which is a far nearer-term binary than any drug event. The stock trades near $0.35 with a strong-buy analyst consensus (mean target ~$6.50) and recent insider buying at $0.80, so upside is real but conditioned on financing survival and a successful filing.
Price Chart
Executive Summary
PrimeC is NeuroSense Therapeutics' (NASDAQ: NRSN) lead — essentially only — drug candidate for ALS, and its Phase 2b PARADIGM data (TDP-43 biomarker hit, HR 0.35 survival benefit, published in JAMA Neurology) are genuinely strong and backed by a strong-buy analyst consensus (mean price target ~$6.50 vs. a ~$0.35 share price). But the stock story is dominated by existential financing and listing risk: the prior 20-F disclosed only ~$0.2M cash and going-concern doubt, Nasdaq has issued delisting notices with a September 29, 2026 compliance deadline, and the next drug binary (Health Canada NDS filing targeted for December 2026, decision ~300 days later) is a submission milestone rather than an approval decision.
How It Works
PrimeC is an oral drug candidate for amyotrophic lateral sclerosis (ALS), the progressive nerve-cell disease. Per company disclosures, it is designed to slow the disease's core biological driver: in the Phase 2b PARADIGM study it produced a statistically significant reduction in TDP-43, a protein whose buildup is a hallmark of ALS, and the company reported a large survival benefit in treated patients. It is being positioned for regulatory submission in Canada first, with a larger US pivotal Phase 3 (PARAGON) cleared to start.
Trial Status
Phase 2b PARADIGM in ALS met its primary biomarker endpoint (statistically significant TDP-43 reduction, p=0.0421 at Day 180, sustained to Day 540 p<0.001) per the June 29, 2026 6-K, alongside previously reported survival benefit (HR 0.35, p=0.0037, ~14.9-month median survival advantage) that was published in JAMA Neurology. The company completed the Health Canada Pre-NDS process (Aug 2026) and targets an NDS filing in December 2026. A separate Phase 2 study of PrimeC in Alzheimer's disease (NCT06185543) was TERMINATED (enrolled 8 subjects). PARAGON Phase 3 record not present in local trial data.
The Two-Sided Case
Upcoming Catalysts
- December 2026 (targeted): Health Canada New Drug Submission filing for PrimeC in ALS
- September 29, 2026: Nasdaq compliance deadline (bid price and market value) — a hard near-term stock-moving date
- Health Canada acceptance and review clock start (post-filing; ~300-day standard review would imply a decision around late 2027)
- Initiation of the pivotal Phase 3 PARAGON study (FDA clearance already granted; timing/financing dependent)
- Any equity financing / PIPE / strategic partnership announcements needed to fund operations
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NeuroSense Therapeutics Ltd. 6-K NRSN ·Originating report